EP3806847A4 - METHODS OF IMPROVING NEUROLOGICAL DISEASES AND DISORDERS - Google Patents

METHODS OF IMPROVING NEUROLOGICAL DISEASES AND DISORDERS Download PDF

Info

Publication number
EP3806847A4
EP3806847A4 EP19819477.1A EP19819477A EP3806847A4 EP 3806847 A4 EP3806847 A4 EP 3806847A4 EP 19819477 A EP19819477 A EP 19819477A EP 3806847 A4 EP3806847 A4 EP 3806847A4
Authority
EP
European Patent Office
Prior art keywords
disorders
methods
neurological diseases
improving neurological
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19819477.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3806847A1 (en
Inventor
Anthony P. FORD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curasen Therapeutics Inc
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of EP3806847A1 publication Critical patent/EP3806847A1/en
Publication of EP3806847A4 publication Critical patent/EP3806847A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19819477.1A 2018-06-14 2019-06-14 METHODS OF IMPROVING NEUROLOGICAL DISEASES AND DISORDERS Withdrawn EP3806847A4 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862685249P 2018-06-14 2018-06-14
US201862685246P 2018-06-14 2018-06-14
US201862685247P 2018-06-14 2018-06-14
US201862686663P 2018-06-18 2018-06-18
US201862686660P 2018-06-18 2018-06-18
US201862686658P 2018-06-18 2018-06-18
US201962825702P 2019-03-28 2019-03-28
US201962825670P 2019-03-28 2019-03-28
US201962825571P 2019-03-28 2019-03-28
US201962825675P 2019-03-28 2019-03-28
PCT/US2019/037358 WO2019241736A1 (en) 2018-06-14 2019-06-14 Methods for improving neurological diseases and disorders

Publications (2)

Publication Number Publication Date
EP3806847A1 EP3806847A1 (en) 2021-04-21
EP3806847A4 true EP3806847A4 (en) 2022-05-04

Family

ID=68842342

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19819477.1A Withdrawn EP3806847A4 (en) 2018-06-14 2019-06-14 METHODS OF IMPROVING NEUROLOGICAL DISEASES AND DISORDERS

Country Status (5)

Country Link
EP (1) EP3806847A4 (https=)
JP (1) JP2021527711A (https=)
AU (1) AU2019287771A1 (https=)
CA (1) CA3100848A1 (https=)
WO (1) WO2019241736A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4208159A4 (en) * 2020-09-01 2024-09-25 Curasen Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses
EP4651867A1 (en) 2023-01-20 2025-11-26 Atrogi AB Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting
GB202302225D0 (en) 2023-02-16 2023-04-05 Atrogi Ab New medical uses
GB202303229D0 (en) 2023-03-06 2023-04-19 Atrogi Ab New medical uses
GB202403169D0 (en) 2024-03-05 2024-04-17 Atrogi Ab New medical uses
WO2025238248A1 (en) 2024-05-17 2025-11-20 Atrogi Ab USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008579A1 (en) * 1992-10-08 1994-04-28 New York University β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
US20120136064A1 (en) * 2010-11-30 2012-05-31 Nixon Ralph A Methods for screening to identify therapeutic agents for alzheimer's disease and use thereof
US20140235726A1 (en) * 2013-02-13 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133226A2 (en) * 2010-04-22 2011-10-27 The Board Of Trustees Of The Leland Stanford Junior University Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
KR20160026897A (ko) * 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008579A1 (en) * 1992-10-08 1994-04-28 New York University β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
US20040248984A1 (en) * 2001-08-29 2004-12-09 Josef Krieglstein Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
US20120136064A1 (en) * 2010-11-30 2012-05-31 Nixon Ralph A Methods for screening to identify therapeutic agents for alzheimer's disease and use thereof
US20140235726A1 (en) * 2013-02-13 2014-08-21 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019241736A1 *

Also Published As

Publication number Publication date
EP3806847A1 (en) 2021-04-21
CA3100848A1 (en) 2019-12-19
WO2019241736A1 (en) 2019-12-19
AU2019287771A1 (en) 2021-01-28
JP2021527711A (ja) 2021-10-14

Similar Documents

Publication Publication Date Title
EP3806847A4 (en) METHODS OF IMPROVING NEUROLOGICAL DISEASES AND DISORDERS
EP3746135A4 (en) METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE
AU2016282790B9 (en) VMAT2 inhibitors for treating neurological diseases or disorders
IL274702A (en) Compounds and Methods for Neurological Diseases
EP3810049A4 (en) SYSTEMS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL267818A (en) Methods for treating neurological disorders
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
AU2019206314B2 (en) Compositions and methods for treating retinal disorders
EP3880250A4 (en) METHODS OF TREATMENT OF IMMUNE-RELATED EYE DISEASES
EP3810777A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
EP3856169A4 (en) Methods of treating myeloproliferative disorders
EP3634986A4 (en) GENE THERAPY FOR EYE DISORDERS
IL268946A (en) Gene therapy for ocular disorders
EP3746478A4 (en) THERAPIES AND METHODS OF TREATING TLR2-MEDIATED DISEASES AND DISORDERS
EP3856189A4 (en) Methods of treating myeloproliferative disorders
AU2017300579A1 (en) Therapeutic agents for neurological and psychiatric disorders
EP3504209A4 (en) METHODS AND COMPOUNDS FOR THE TREATMENT OF ALCOHOL USE DISORDERS AND RELATED ILLNESSES
HK40046580A (en) Methods for improving neurological diseases and disorders
HK40084032A (en) Methods for improving neurological diseases and disorders
EP3931214A4 (en) GENE THERAPY FOR ADDICTION DISORDERS
HK40074660A (en) Methods for the treatment of apoc3-related diseases and disorders
EP3622088A4 (en) BIOMARKERS FOR ANTI-TNF THERAPY FOR NETWORK DISEASES
HK40015417A (en) Methods for the treatment of neurological disorders
HK40038636A (en) Compositions and methods for neurological diseases
HK40054637A (en) Compositions and methods for treating inflammatory neurological disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046580

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031380000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20220404

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20220328BHEP

Ipc: A61K 31/5375 20060101ALI20220328BHEP

Ipc: A61K 31/165 20060101ALI20220328BHEP

Ipc: A61K 31/138 20060101ALI20220328BHEP

Ipc: A61K 31/404 20060101ALI20220328BHEP

Ipc: A61K 31/166 20060101ALI20220328BHEP

Ipc: A61K 31/137 20060101AFI20220328BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240604